Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world assessment of perioperative durvalumab plus gemcitabine/cisplatin neoadjuvant therapy in muscle-invasive bladder cancer in Japan
jRCT1030250649Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in muscle-invasive bladder carcinoma (MIBC), sponsored by AstraZeneca. Primary endpoint: Event-free survival (EFS) at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on jRCT1030250649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030250649.